CO2023015501A2 - Lípidos catiónicos y composiciones de estos - Google Patents

Lípidos catiónicos y composiciones de estos

Info

Publication number
CO2023015501A2
CO2023015501A2 CONC2023/0015501A CO2023015501A CO2023015501A2 CO 2023015501 A2 CO2023015501 A2 CO 2023015501A2 CO 2023015501 A CO2023015501 A CO 2023015501A CO 2023015501 A2 CO2023015501 A2 CO 2023015501A2
Authority
CO
Colombia
Prior art keywords
formula
compositions
lipids
cationic lipids
capsid
Prior art date
Application number
CONC2023/0015501A
Other languages
English (en)
Inventor
Matthew G Stanton
Birte Nolting
Andrew Milstead
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of CO2023015501A2 publication Critical patent/CO2023015501A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En la presente descripción se proporcionan lípidos que tienen la Fórmula I o la Fórmula Ia: I o Ia y sales farmacéuticamente aceptables de estos, en donde R’, R1, R2, R3, R4, R5, R6a, R6b, X1, X2, y n son como se define en la presente descripción para la Fórmula I y Fórmula Ia, respectivamente. También se proporcionan en la presente descripción composiciones de nanopartículas lipídicas (LNP) que comprenden lípidos que tienen la Fórmula I o Ia y un vector no viral sin cápside (p. ej., ADNec). En un aspecto de cualquiera de los aspectos o modalidades de la presente descripción, estas LNP pueden usarse para suministrar un vector de ADN no viral, sin cápside, en un sitio diana de interés (p. ej., célula, tejido, órgano y lo similar).
CONC2023/0015501A 2021-04-20 2023-11-16 Lípidos catiónicos y composiciones de estos CO2023015501A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163176943P 2021-04-20 2021-04-20
US202163217869P 2021-07-02 2021-07-02
PCT/US2022/025455 WO2022226008A2 (en) 2021-04-20 2022-04-20 Cationic lipids and compositions thereof

Publications (1)

Publication Number Publication Date
CO2023015501A2 true CO2023015501A2 (es) 2023-11-30

Family

ID=83723777

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0015501A CO2023015501A2 (es) 2021-04-20 2023-11-16 Lípidos catiónicos y composiciones de estos

Country Status (9)

Country Link
EP (1) EP4326235A2 (es)
JP (1) JP2024517644A (es)
KR (1) KR20230172570A (es)
AU (1) AU2022262592A1 (es)
BR (1) BR112023021504A2 (es)
CA (1) CA3215324A1 (es)
CO (1) CO2023015501A2 (es)
IL (1) IL307758A (es)
WO (1) WO2022226008A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024119103A1 (en) * 2022-12-01 2024-06-06 Generation Bio Co. Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
WO2024119051A1 (en) * 2022-12-01 2024-06-06 Generation Bio Co. Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013237874B2 (en) * 2012-03-29 2018-01-18 Translate Bio, Inc. Lipid-derived neutral nanoparticles
WO2019188867A1 (ja) * 2018-03-27 2019-10-03 日油株式会社 細胞内動態を改善した新規カチオン性脂質
AU2021307952A1 (en) * 2020-07-17 2023-03-02 Generation Bio Co. Methods for encapsulating polynucleotides into reduced sizes of Lipid nanoparticles and novel formulation thereof

Also Published As

Publication number Publication date
IL307758A (en) 2023-12-01
JP2024517644A (ja) 2024-04-23
KR20230172570A (ko) 2023-12-22
AU2022262592A1 (en) 2023-11-09
EP4326235A2 (en) 2024-02-28
WO2022226008A2 (en) 2022-10-27
CA3215324A1 (en) 2022-10-27
BR112023021504A2 (pt) 2023-12-19
WO2022226008A3 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
CO2023015501A2 (es) Lípidos catiónicos y composiciones de estos
BR112022007481A2 (pt) Lipídios ionizáveis e composições de nanopartículas dos mesmos
BR112022019369A2 (pt) Lipídios e composições de nanopartículas dos mesmos
Mével et al. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
CY1118102T1 (el) Αλατα διαμινιου φαινοθειαζινης και η χρηση αυτων
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
CY1114643T1 (el) Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων
Masotti et al. Physicochemical and biological study of selected hydrophobic polyethylenimine-based polycationic liposomes and their complexes with DNA
AR048596A1 (es) Atenuacion sinergica del virus de estomatitis vesiculosa, sus vectores y sus composiciones inmunogenas
CY1105628T1 (el) Θεραπεια για ανθρωπινους καρκινους χρησιμοποιωντας cisplatin και αλλα φαρμακα ή γονιδια ενθυλακωμενα σε λιποσωματα
BR112012005029A2 (pt) ácidos sulfo-peroxicarboxílicos, seu preparo e métodos de uso como agentes alvejantes e antimicrobianos.
US20220168231A1 (en) Synthetic lipids for mrna delivery
Zavradashvili et al. Library of cationic polymers composed of polyamines and arginine as gene transfection agents
CO6700851A2 (es) Conjugado de naloxol-peg cristalino
MX2022014484A (es) Lipidos nuevos y composiciones de nanoparticulas de estos.
ES2952055T3 (es) Composiciones y métodos para la sensibilización viral
AU2021252496A1 (en) Carriers for efficient nucleic acid delivery
CL2022000319A1 (es) Derivados de amidas híbridas de anfotericina b
JP6873418B2 (ja) 遺伝子導入された細胞の製造方法及びポリエチレンイミンの置換体ポリマー
ES2542864T3 (es) Composición portadora de administración rápida de ácidos nucleicos
PT1946761E (pt) Composição veicular para o transporte de ácido nucleico
CN104364232B (zh) 用于癌症治疗的激酶抑制剂
Yang et al. Inhibition of proliferation and migration of tumor cells through phenylboronic acid-functionalized polyamidoamine-mediated delivery of a therapeutic DNAzyme Dz13
Barbeau et al. Synthesis of a novel archaeal tetraether-type lipid containing a diorthoester group as a helper lipid for gene delivery